Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 18 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Petanidis, Savvas [Clear All Filters]
(2015).
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer..
J Cancer. 8(18), 3648-3656.
(2017).
(2019).
Carboplatin chemoresistance is associated with CD11b/Ly6C myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells..
Mol Immunol. 118, 99-109.
(2020). Connection between PD-L1 expression and standardized uptake value in NSCLC: an early prognostic treatment combination..
Expert Rev Respir Med.
(2020). Dual photothermal MDSCs-targeted immunotherapy inhibits lung immunosuppressive metastasis by enhancing T-cell recruitment..
Nanoscale. 12(13), 7051-7062.
(2020). Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation..
Oncotarget. 11(29), 2847-2862.
(2020). Pleurodesis and Immunotherapy in NSCLC; Medical Thoracoscopy or VATS?.
J Cancer. 11(6), 1606-1613.
(2020). Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer..
J Cancer. 11(11), 3407-3415.
(2020). Kras-driven intratumoral heterogeneity triggers infiltration of M2 polarized macrophages via the circHIPK3/PTK2 immunosuppressive circuit..
Sci Rep. 11(1), 15455.
(2021). Treg-dependent immunosuppression triggers effector T cell dysfunction via the STING/ILC2 axis..
Clin Immunol. 222, 108620.
(2021). Engineered multifunctional nanocarriers for controlled drug delivery in tumor immunotherapy..
Front Oncol. 12, 1042125.
(2022). Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies..
Oncol Lett. 23(6), 196.
(2022). Molecular and Immune Phenotypic Modifications during Metastatic Dissemination in Lung Carcinogenesis..
Cancers (Basel). 14(15),
(2022).
(2022). Immunoengineering via Chimeric Antigen Receptor-T Cell Therapy: Reprogramming Nanodrug Delivery..
Pharmaceutics. 15(10),
(2023). Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization..
Front Immunol. 14, 1325360.
(2023).